<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809183</url>
  </required_header>
  <id_info>
    <org_study_id>TRCA-101</org_study_id>
    <secondary_id>2015-004327-31</secondary_id>
    <nct_id>NCT02809183</nct_id>
  </id_info>
  <brief_title>Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of TRC101 in Subjects With Chronic Kidney Disease and Low Serum Bicarbonate Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tricida, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tricida, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled, parallel-design, 6-arm, fixed dose study. The
      study will enroll approximately 130 adult male and female subjects with Stage 3 or 4 chronic
      kidney disease and low serum bicarbonate levels. The study will be conducted in two parts. In
      Part 1 study drug dosing (TRC101 or placebo) will continue for 14 days twice daily. In Part 2
      study drug dosing (TRC101 or placebo) will continue for 14 days once daily.

      The maximum study duration is anticipated to be up to 42 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this first-in-human study is to evaluate the safety and tolerability of TRC101. The primary outcome measure is the comparison across dose groups of the cumulative percentage of treatment-emergent adverse events.</measure>
    <time_frame>Through study completion, up to 4 weeks.</time_frame>
    <description>The number and percentage of subjects who reported treatment-emergent adverse events will be summarized by system organ class and preferred term; as well as by severity, causality, seriousness, and action taken with regard to study drug. All analyses will be descriptive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome measure is the change from baseline in serum bicarbonate to the end of 2-week treatment period within individual TRC101 dose group.</measure>
    <time_frame>Through treatment period completion, up to 2 weeks.</time_frame>
    <description>Efficacy data will be summarized by dose group based on the randomized treatment group assignment. Descriptive statistics of efficacy data will be provided for all scheduled time points.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Acidosis</condition>
  <arm_group>
    <arm_group_label>Placebo-BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRC101 (Dose 1-BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRC101 (Dose 2-BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRC101 (Dose 3-BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRC101 (Dose 2-QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered once daily (QD) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered once daily (QD) for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral suspension</description>
    <arm_group_label>Placebo-BID</arm_group_label>
    <arm_group_label>Placebo-QD</arm_group_label>
    <other_name>microcrystalline cellulose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC101</intervention_name>
    <description>oral suspension</description>
    <arm_group_label>TRC101 (Dose 1-BID)</arm_group_label>
    <arm_group_label>TRC101 (Dose 2-BID)</arm_group_label>
    <arm_group_label>TRC101 (Dose 3-BID)</arm_group_label>
    <arm_group_label>TRC101 (Dose 2-QD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) of 20 to &lt;60 mL/min/1.73m2

          -  Serum bicarbonate level of 12 to 20 mEq/L

        Exclusion Criteria:

          -  Any level of low serum bicarbonate that, in the opinion of the Investigator, requires
             emergency intervention.

          -  Severe comorbid conditions other than chronic kidney disease.

          -  Chronic obstructive pulmonary disease.

          -  Anticipated changes in doses of any of the following drugs or drug classes: diuretics,
             non-ophthalmic carbonic anhydrase inhibitors, oral diabetes drugs, antihypertensive
             drugs, antacids, H2-blockers, or proton pump inhibitors.

          -  Excluded drugs or drug classes: insulin, non-daily or &quot;as needed&quot; diuretics, herbal
             products, dietary supplements, multivitamins, naturopathic remedies, sodium
             bicarbonate, potassium citrate, sodium citrate or other alkali therapy, non-steroidal
             anti-inflammatory drugs (NSAIDs), fiber supplements, laxatives, calcium and magnesium
             supplements, or electrolyte binders and other binder drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuri Stasiv, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tricida, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site 1</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site 3</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site 4</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site 5</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site 6</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <disposition_first_submitted>November 30, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 6, 2017</disposition_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolic acidosis</keyword>
  <keyword>serum bicarbonate</keyword>
  <keyword>kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

